Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Trial to Assess Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors (NEXIRI 2)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2012 by Centre Val d'Aurelle - Paul Lamarque
Sponsor:
Information provided by (Responsible Party):
Centre Val d'Aurelle - Paul Lamarque
ClinicalTrials.gov Identifier:
NCT01715441
First received: October 19, 2012
Last updated: February 4, 2014
Last verified: October 2012

October 19, 2012
February 4, 2014
September 2012
March 2015   (final data collection date for primary outcome measure)
Non-progression rate [ Time Frame: At 2 months ] [ Designated as safety issue: No ]
To evaluate the non-progression rate at 2 months according to RECIST criteria (Version 1.1)
Same as current
Complete list of historical versions of study NCT01715441 on ClinicalTrials.gov Archive Site
  • Disease control rate [ Time Frame: At 2 months ] [ Designated as safety issue: No ]
    According to RECIST criteria (Version 1.1)
  • Treatment-related toxicity [ Time Frame: At 6 months ] [ Designated as safety issue: Yes ]
    According to NCI CTC V4.0
  • Overall survival [ Time Frame: At 6 months ] [ Designated as safety issue: No ]
    Overall survival is defined as the time from the date of inclusion to the date of death from any cause.
  • Quality of life [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Using the EORTC QLQ-C30 questionnaire
  • Progression Free Survival [ Time Frame: At 6 months ] [ Designated as safety issue: No ]
    Progression Free Survival is defined as the time from the date of inclusion to first documentation of objective tumor progression or to death due to progression.
  • Response rate [ Time Frame: At 2 months ] [ Designated as safety issue: No ]
    According to RECIST criteria (Version 1.1)
Same as current
Cmax and Tmax of sorafenib and irinotecan [ Time Frame: Up to 3 months ] [ Designated as safety issue: No ]
Same as current
 
A Trial to Assess Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
A Randomized Phase II Trial Assessing Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors After Failure of All Drugs Known to be Effective

The aim of this multicenter randomized phase II trial is to determine the efficacy of sorafenib and irinotecan combination versus irinotecan monotherapy or versus sorafenib monotherapy in metastatic colorectal cancer patients with KRAS mutated tumors after failure of all active drugs known to be effective.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
  • Drug: Sorafenib and irinotecan combination
  • Drug: Sorafenib monotherapy
  • Drug: Irinotecan monotherapy
  • Active Comparator: Irinotecan monotherapy
    Intravenous infusion irinotecan 180 mg/m2 over 90 minutes (D1=D15) with cross over to irinotecan and sorafenib combination at progression.
    Intervention: Drug: Irinotecan monotherapy
  • Active Comparator: Sorafenib monotherapy
    Oral sorafenib 400 mg twice daily (total dose 800 mg/day) with cross over to irinotecan and sorafenib combination at progression
    Intervention: Drug: Sorafenib monotherapy
  • Experimental: Sorafenib and irinotecan combination

    Intravenous infusion irinotecan 120 mg/m2 over 90 minutes (D1=D15) at Cycle 1, 150 mg/m² at C2 if no diarrhea > grade 1 and no other toxicity > grade 2, and 180 mg/m² at C3 in the same conditions

    • Oral sorafenib 400 mg twice daily (total dose 800 mg/day) from C1. 1 cycle = 15 days and 1 course = 4 weeks.
    Intervention: Drug: Sorafenib and irinotecan combination
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
160
September 2015
March 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female ≥ 18 years old
  • Histologically confirmed diagnosis of colorectal cancer
  • Asymptomatic or resected primary tumor
  • Metastatic colorectal cancer patient not eligible for curative surgery
  • At least one target lesion:

    • Unidimensionally measurable on cross-sectional imaging
    • In an area not previously irradiated
  • Disease progression after failure of active drugs (5-Fu or 5-Fu prodrugs, irinotecan, oxaliplatin, bevacizumab)
  • Patients with bone metastases are eligible if they have other measurable lesions
  • WHO performance status ≤ 2
  • Confirmation of KRAS mutation in codons 12 or 13 in the primary tumor or metastases
  • Total bilirubin ≤ 1.5 ULN, ALT or AST ≤ 2.5 ULN (or < 5 in case of liver impairment)
  • Haemoglobin ≥ 10 g/dL, neutrophils ≥ 1,500/mm3, platelets ≥ 100,000/mm3
  • Serum creatinine ≤ 1.5 ULN
  • Negative pregnancy test in women of childbearing potential
  • Use of an effective contraceptive method during the whole treatment and up to 3 months after the completion of treatment in males and females
  • Life expectancy of at least 3 months
  • Informed consent signed prior any study specific procedures
  • Tumor evaluation should be performed within 3 weeks prior to starting treatment

Exclusion Criteria:

  • History of Gilbert's syndrome
  • Symptomatic brain metastases or carcinomatous meningitis
  • Bone-only metastases
  • History or presence of other cancers within the past 5 years (except curatively treated non-melanoma skin cancer and in situ cervical cancer)
  • Prior surgery or radiotherapy within 4 weeks before entering the study
  • Cardiac arrhythmia requiring treatment (except for beta-blockers and digoxin), unstable cardiac disease, myocardial infarction within the previous 6 months, > grade II NYHA heart failure, uncontrolled hypertension
  • Kalemia lower than normal serum potassium value
  • From ECG, QTc interval > 470 ms
  • History of acute or chronic pancreatitis
  • History of epileptic seizures requiring long-term anticonvulsant therapy
  • History of organ transplantation with use of immunosuppression therapy
  • Severe bacterial or fungal infection (Grade > 2 NCI-CTCAE v.4.0)
  • Known HIV infection
  • Long-term use of CYP 3A4 enzyme-inducing agents such as rifampicin, St. John's Wort (hypericum perforatum), phenytoin, carbamazepine, phenobarbital, dexamethasone, and ketoconazole
  • Pregnant or breastfeeding women
  • Bowel malabsorption or extended bowel resection that could affect the absorption of sorafenib, occlusive syndrome, inability to take oral medications
  • Inflammatory bowel disease with chronic diarrhea (NCI-CTCAE v.4.0)
  • Participation in another clinical trial 30 days prior to study entry
  • Concurrent treatment with any other investigational product or anticancer therapy (except for irinotecan or sorafenib)
  • Psychological, social, geographical disorders or any other condition that would preclude study compliance (treatment administration and study follow-up).
Both
18 Years and older
No
Contact: Jean-Pierre Bleuse, MD 33 4 67 61 23 44 Jean-Pierre.Bleuse@montpellier.unicancer.fr
France
 
NCT01715441
NEXIRI2, 2012-000644-94
Yes
Centre Val d'Aurelle - Paul Lamarque
Centre Val d'Aurelle - Paul Lamarque
Not Provided
Principal Investigator: Emmanuelle SAMALIN, MD CRLC Val d'Aurelle-Paul Lamarque
Study Chair: Marc YCHOU, MD, CRLC Val d'Aurelle
Centre Val d'Aurelle - Paul Lamarque
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP